Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BACKGROUND MicroRNA-32 (miR-32) induces cell proliferation and metastasis in
hepatocellular carcinoma
(
HCC
), but the detailed mechanisms of miR-32 in regulating oncogenesis and development of
HCC
have not been clarified. The aim of this study was to investigate the effects of miR-32 on
HCC
and its clinical pathological significance, as well as to determine the functional connection between miR-32 and ADAMTS9 in
HCC
. MATERIAL AND METHODS Quantitative RT-PCR was used to assess the expression levels of miR-32 in
HCC
tissues, adjacent non-cancerous tissues, and liver cancer cell lines. In vitro cell proliferation, migration, and invasion assays were performed to confirm the biological functions of miR-32. Quantitative RT-PCR, Western blot analysis, and luciferase reporter assays were used to evaluate the role of miR-32 in the regulation of ADAMTS9. RESULTS miR-32 was highly expressed in
HCC
tissues compared with corresponding adjacent non-cancerous tissues. Over-expression of miR-32 was also found in 3 human liver cancer cell lines: SMMC-7721, Huh7, and HepG2. Moreover, increasing expression of miR-32 in
HCC
tissues was related to shorter overall survival. In vitro over-expression of miR-32 promoted cell proliferation, migration, and invasion; however, the under-expression of miR-32 revealed the opposite effects. Dual-luciferase reporter assay indicated that miR-32 can directly bind to the 3'-UTR of ADAMTS9. Western blot analysis showed that over-expression of miR-32 decreased expression of
ADAMTS9 protein
. Rescue tests further verified the connection between miR-32 and ADAMTS9. CONCLUSIONS Our data indicate that miR-32 accelerates progression in
HCC
by targeting ADAMTS9, and the abnormal expression of miR-32 is correlated with prognosis and could become a potential therapeutic target.
...
PMID:MicroRNA-32 Regulates Development and Progression of Hepatocellular Carcinoma by Targeting ADAMTS9 and Affects Its Prognosis. 3039 68